ABIONYX Pharma Provides an Update on Its Operations and Cash Position for the First Quarter of 2026
Consolidated revenue of €0.8 million as of the end of March 2026 and €2.6 million secured for the year
Cash position of €2.8 million as of March 31, 2026, stable compared to December 31, 2025, before receipt of €0.7 million in research tax credits
Financial visibility horizon extended to the end of 2028 given the funding 100% secured from the capital increase with maintenance of preemptive subscription rights and the non-dilutive loan announced on May 27
Regulatory News:
